The company beat analyst expectations. But did the analysts expect them to write off one of their pipeline drugs as worthless? HAHAHA. These financials are such a joke. if this company is valued as an orphan CF company, that's fine. But a fair valuation for that type of company in that type of position is maybe $5 billion at the most, and probably closer to SRPT-like market cap. At a $17B market cap you're expected to have a little bit more than just hope. Like growing revenues and profits right now. Not 2016 or 2017 or whatever.